First Patient Dosed With Drug Combo in Phase 2 Gastric Cancer Trial

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.

Related Keywords

United States ,American ,Jennifer Buell ,Yelena Janjigian ,Gastrointestinal Oncology Service ,American Cancer Society ,Memorial Sloan Kettering Cancer Center ,Mink Therapeutics ,American Cancer ,Chief Gastrointestinal Oncology Service ,Vitrakvi Continues ,Improve Survival ,Slower Infusion ,Antiemetic Drugs May Help With Nausea ,News ,Gastric Cancer ,Agent 797 ,Phase 2 Trial ,Oesophageal ,